Skip to content

Perspective Therapeutics CATX Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

Eli Lilly logo
Eli LillyLLY
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
Immunome logo
ImmunomeIMNM
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
Lantheus Holdings logo
Lantheus HoldingsLNTH
uniQure logo
uniQureQURE

Other financials

Income statement

See full
Revenue$2.2M+27.3%
Gross profit$738.0K+78.3%
Operating income-$28.3M-29.5%
Net income-$26.2M-44.1%
EPS (diluted)-$0.250.0%

Balance sheet

See full
Cash & equivalents$54.0M+21.5%
Total debt$4.2M+10.9%
Total equity$347.4M+22.1%
Total assets$410.8M+24.7%

Cash flow

See full
Operating cash flow-$31.5M-45.8%
CapEx$6.9M+47.3%
Free cash flow-$38.3M-46.1%

Valuation

See full
Market cap$342.14M+33.2%
Enterprise value$292.34M+35.2%
P/S34.2×+19.6×

Profitability

See full
Gross margin33.1%-7.1pp
Operating margin-292.7%-553pp
Net margin-218.4%-781pp
FCF margin-1,073.3%

Returns & leverage

See full
Return on equity-35.2%+2.3pp
Debt / equity0.0×
Current ratio8.7×-8.3×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Perspective Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Perspective Therapeutics's software and technology licenses, net?
Perspective Therapeutics (CATX) reported software and technology licenses, net of $490K in Q1 2026.
How has Perspective Therapeutics's software and technology licenses, net changed year-over-year?
Perspective Therapeutics's software and technology licenses, net increased by 33.9% year-over-year, from $366K to $490K.
What is the long-term trend for Perspective Therapeutics's software and technology licenses, net?
Over 5 years (2020 to 2025), Perspective Therapeutics's software and technology licenses, net has grown at a 32.5% compound annual growth rate (CAGR), from $119K to $486K.